PubMed Health⌕ Search

Biomedical subjects

R Eberhardt

Publications and source records attributed to R Eberhardt.

47 records · Page 3Linked to original sources
PubMedDate not supplied

Effect of oral bismuth subsalicylate on Campylobacter pylori and on healing and relapse rate of peptic ulcer.

A controlled, open clinical trial was performed to compare the effect of oral bismuth subsalicylate (600 mg three times daily) with that of cimetidine (800 mg/d) on Campylobacter pylori, ulcer healing, and rate of ulcer relapse in 49 patients with peptic ulcer. At the first endoscopic examination (to confirm the diagnosis) and at the second (after 4 weeks of treatment), biopsy specimens were taken from the gastric antrum; the presence of C. pylori in culture and the rate of ulcer healing were determined. The rate of ulcer relapse was determined by a 9-month follow-up examination. After cessation of treatment a significant rate of healing was seen in both treatment groups: 73% in the bismuth group and 65% in the cimetidine group. Ulcer healing was confirmed by endoscopic examination. Before therapy the number of C. pylori-positive cases (61%) was identical from the two groups; however, after 4 weeks of treatment, 75% of the previously culture-positive cases in the bismuth group reverted to negative (a statistically significant change), whereas only 40% of those in the cimetidine group reverted (not statistically significant). The rate of clearance of C. pylori was statistically significant for the 29 patients with healed ulcers and correlated strongly with ulcer healing in the bismuth group only. The rate of relapse after 9 months of follow-up was 13% in the group treated with bismuth subsalicylate--a figure significantly lower than the 54% rate of relapse in the group treated with cimetidine.

Adult↗
PubMedDate not supplied

Citicoline in the treatment of Parkinson's disease.

Eighty-five patients with an established diagnosis of primary Parkinson's disease were randomly assigned to receive their usual dose of levodopa (mean, 381 mg daily) plus 1,200 mg of citicoline daily or half their usual dose of levodopa (mean, 196 mg daily) plus the citicoline. Results of the Webster Rating Scale, a pegboard test, drawing, writing, and walking tests, a test of emotional state, and an overall assessment, administered before and after four weeks of treatment, revealed no significant between-group differences. Improvements on the tests were shown by more patients who received half their levodopa dose plus citicoline than by those who continued to receive their usual levodopa dose plus the citicoline. It is concluded that the levodopa-saving effect of citicoline could be used to decrease the incidence of side effects and retard the loss of efficacy of levodopa in long-term treatment.

Adult↗
PubMedDate not supplied

[Flurbiprofen and indomethacin in chronic polyarthritis and gonarthrosis - a comparative multicentric double-blind cross-over study].

In two multicenter double-blind cross-over studies efficacy and safety of flurbiprofen and indomethacin were compared. Nineteen patients with rheumatoid arthritis and twenty with osteoarthrosis of the knee were treated. Both drugs were effective and almost equal. Also safety was good, however three patients on indomethacin and one on flurbiprofen had to be withdrawn from the trial because of side-effects.

Aged↗